



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Lianhmingthangi Assistant Drugs Inspector (food and Drugs), CMO Office
CMO Office
Siaha District, Mizoram- 796901
2. Serial No. and date of Inspector's memorandum : SD/25/06N-DRUGS , 08-AUG-2025
3. Number of Sample : Not mentioned
4. Date of receipt : 01-SEP-2025
5. Names of drugs purporting to be contained in the sample : Telmisartan Tablets IP 40mg (Savtel 40 Tablets)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-GUW/LS/2025-26/1062	26/1040	PT- 40584	Feb-2024 Jan-2026	NA	Pharmaroots Healthcare, Khasra No. 411, Village Tipra, P.O. Barotiwala, Tehsil Baddi, Distt. Solan H.P.

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
(the packet or on portion of sample or container)

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 08-Oct-2025 To 12-Dec-2025

COMPOSITION : Each film coated tablet contains:
Telmisartan IP 40 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, scored on one surface, film coated tablets, in alu-alu strip.	
2	Identification	Gives positive test for Telmisartan.	
3	Average weight	0.35008 g	
4	Uniformity of weight	Complies.	+5 % of Average weight
5	Dissolution	Does not comply. (Average release of Telmisartan is found 64.46% of claim)	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Telmisartan	41.78 mg/Tablet	40 mg/Tablet	104.45	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is not of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample does not comply as per I.P. 2022 with respect to the test for "Dissolution" of Telmisartan.

Date: 26-DEC-2025

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

Report in the red colored paper indicates the sample is not of standard quality.

END OF REPORT

